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Abstract: High-sensitivity cardiac troponin assay development enables determination of 
biological variation in healthy populations, more accurate interpretation of clinical results and 
points towards earlier diagnosis and rule-out of acute myocardial infarction. In this paper, we 
report on preliminary tests of an immunoassay analyzer employing an optimized LED 
excitation to measure on a standard troponin I and a novel research high-sensitivity troponin I 
assay. The limit of detection is improved by factor of 5 for standard troponin I and by factor 
of 3 for a research high-sensitivity troponin I assay, compared to the flash lamp excitation. 
The obtained limit of detection was 0.22 ng/L measured on plasma with the research high-
sensitivity troponin I assay and 1.9 ng/L measured on tris-saline-azide buffer containing 
bovine serum albumin with the standard troponin I assay. We discuss the optimization of 
time-resolved detection of lanthanide fluorescence based on the time constants of the system 
and analyze the background and noise sources in a heterogeneous fluoroimmunoassay. We 
determine the limiting factors and their impact on the measurement performance. The 
suggested model can be generally applied to fluoroimmunoassays employing the dry-cup 
concept. 
© 2017 Optical Society of America 
OCIS codes: (120.3890) Medical optics instrumentation; (170.4580) Optical diagnostics for medicine; (170.6280) 
Spectroscopy, fluorescence and luminescence. 
References and links 
1. K. Thygesen, J. S. Alpert, A. S. Jaffe, M. L. Simoons, B. R. Chaitman, H. D. White, H. A. Katus, B. Lindahl, D. 
A. Morrow, P. M. Clemmensen, P. Johanson, H. Hod, R. Underwood, J. J. Bax, R. O. Bonow, F. Pinto, R. J. 
Gibbons, K. A. Fox, D. Atar, L. K. Newby, M. Galvani, C. W. Hamm, B. F. Uretsky, P. G. Steg, W. Wijns, J. P. 
Bassand, P. Menasché, J. Ravkilde, E. M. Ohman, E. M. Antman, L. C. Wallentin, P. W. Armstrong, M. L. 
Simoons, J. L. Januzzi, M. S. Nieminen, M. Gheorghiade, G. Filippatos, R. V. Luepker, S. P. Fortmann, W. D. 
Rosamond, D. Levy, D. Wood, S. C. Smith, D. Hu, J. L. Lopez-Sendon, R. M. Robertson, D. Weaver, M. 
Tendera, A. A. Bove, A. N. Parkhomenko, E. J. Vasilieva, and S. Mendis; Joint ESC/ACCF/AHA/WHF Task 
Force for the Universal Definition of Myocardial Infarction, “Third universal definition of myocardial 
infarction,” Circulation 126(16), 2020–2035 (2012). 
2. P. M. McKie, D. M. Heublein, C. G. Scott, M. L. Gantzer, R. A. Mehta, R. J. Rodeheffer, M. M. Redfield, J. C. 
Burnett, Jr., and A. S. Jaffe, “Defining high-sensitivity cardiac troponin concentrations in the community,” Clin. 
Chem. 59(7), 1099–1107 (2013). 
3. D. M. Kimenai, R. M. Henry, C. J. van der Kallen, P. C. Dagnelie, M. T. Schram, C. D. Stehouwer, J. D. van 
Suijlen, M. Niens, O. Bekers, S. J. Sep, N. C. Schaper, M. P. van Dieijen-Visser, and S. J. Meex, “Direct 
comparison of clinical decision limits for cardiac troponin T and I,” Heart 102(8), 610–616 (2016). 
4. M. Franzini, V. Lorenzoni, S. Masotti, C. Prontera, D. Chiappino, D. D. Latta, M. Daves, I. Deluggi, M. Zuin, L. 
Ferrigno, A. Mele, F. Marcucci, C. A. Caserta, P. Surace, A. Messineo, G. Turchetti, C. Passino, M. Emdin, and 
A. Clerico, “The calculation of the cardiac troponin T 99th percentile of the reference population is affected by 
age, gender, and population selection: A multicenter study in Italy,” Clin. Chim. Acta 438, 376–381 (2015). 
5. T. Zeller, F. Ojeda, F. J. Brunner, P. Peitsmeyer, T. Münzel, H. Binder, N. Pfeiffer, M. Michal, P. S. Wild, S. 
Blankenberg, and K. J. Lackner, “High-sensitivity cardiac troponin I in the general population-defining reference 
                                                                              Vol. 8, No. 8 | 1 Aug 2017 | BIOMEDICAL OPTICS EXPRESS 3749 
#297255  
Journal © 2017
https://doi.org/10.1364/BOE.8.003749 
Received 2 Jun 2017; revised 6 Jul 2017; accepted 17 Jul 2017; published 20 Jul 2017 
populations for the determination of the 99th percentile in the Gutenberg Health Study,” Clin. Chem. Lab. Med. 
53(5), 699–706 (2015). 
6. F. S. Apple, P. O. Collinson; IFCC Task Force on Clinical Applications of Cardiac Biomarkers, “Analytical 
characteristics of high-sensitivity cardiac troponin assays,” Clin. Chem. 58(1), 54–61 (2012). 
7. R. Twerenbold, A. Jaffe, T. Reichlin, M. Reiter, and C. Mueller, “High-sensitive troponin T measurements: what 
do we gain and what are the challenges?” Eur. Heart J. 33(5), 579–586 (2012). 
8. T. Keller, T. Zeller, F. Ojeda, S. Tzikas, L. Lillpopp, C. Sinning, P. Wild, S. Genth-Zotz, A. Warnholtz, E. 
Giannitsis, M. Möckel, C. Bickel, D. Peetz, K. Lackner, S. Baldus, T. Münzel, and S. Blankenberg, “Serial 
Changes in Highly Sensitive Troponin I Assay and Early Diagnosis of Myocardial Infarction,” JAMA 306(24), 
2684–2693 (2011). 
9. K. Wildi, M. R. Gimenez, R. Twerenbold, T. Reichlin, C. Jaeger, A. Heinzelmann, C. Arnold, B. Nelles, S. 
Druey, P. Haaf, P. Hillinger, N. Schaerli, P. Kreutzinger, Y. Tanglay, T. Herrmann, Z. Moreno Weidmann, L. 
Krivoshei, M. Freese, C. Stelzig, C. Puelacher, K. Rentsch, S. Osswald, and C. Mueller, “Misdiagnosis of 
myocardial infarction related to limitations of the current regulatory approach to define clinical decision values 
for cardiac troponin,” Circulation 131(23), 2032–2040 (2015). 
10. T. Zeller, H. Tunstall-Pedoe, O. Saarela, F. Ojeda, R. B. Schnabel, T. Tuovinen, M. Woodward, A. Struthers, M. 
Hughes, F. Kee, V. Salomaa, K. Kuulasmaa, and S. Blankenberg; MORGAM Investigators, “High population 
prevalence of cardiac troponin I measured by a high-sensitivity assay and cardiovascular risk estimation: the 
MORGAM Biomarker Project Scottish Cohort,” Eur. Heart J. 35(5), 271–281 (2014). 
11. P. St-Louis, “Status of point-of-care testing: promise, realities, and possibilities,” Clin. Biochem. 33(6), 427–440 
(2000). 
12. P. von Lode, “Point-of-care immunotesting: Approaching the analytical performance of central laboratory 
methods,” Clin. Biochem. 38(7), 591–606 (2005). 
13. S. Aldous, A. Mark Richards, P. M. George, L. Cullen, W. A. Parsonage, D. Flaws, C. M. Florkowski, R. W. 
Troughton, J. W. O’Sullivan, C. M. Reid, L. Bannister, and M. Than, “Comparison of new point-of-care 
troponin assay with high sensitivity troponin in diagnosing myocardial infarction,” Int. J. Cardiol. 177(1), 182–
186 (2014). 
14. S. Hjortshøj, P. Venge, and J. Ravkilde, “Clinical performance of a new point-of-care cardiac troponin I assay 
compared to three laboratory troponin assays,” Clin. Chim. Acta 412(3-4), 370–375 (2011). 
15. I. Hemmilä and V. Laitala, “Progress in lanthanides as luminescent probes,” J. Fluoresc. 15(4), 529–542 (2005). 
16. J.-C. G. Bünzli, “Lanthanide luminescence for biomedical analyses and imaging,” Chem. Rev. 110(5), 2729–
2755 (2010). 
17. L. Seveus, M. Väisälä, S. Syrjänen, M. Sandberg, A. Kuusisto, R. Harju, J. Salo, I. Hemmilä, H. Kojola, and E. 
Soini, “Time-Resolved Fluorescence Imaging of Europium Chelate Label in Immunohistochemistry and In Situ 
Hybridization,” Cytometry 13(4), 329–338 (1992). 
18. R. Connally, D. Veal, and J. Piper, “Flash lamp-excited time-resolved fluorescence microscope suppresses 
autofluorescence in water concentrates to deliver an 11-fold increase in signal-to-noise ratio,” J. Biomed. Opt. 
9(4), 725–734 (2004). 
19. S. W. Kettlitz, C. Moosmann, S. Valouch, and U. Lemmer, “Sensitivity improvement in fluorescence-based 
particle detection,” Cytometry A 85(9), 746–755 (2014). 
20. D. Jin, R. Connally, and J. Piper, “Practical time-gated luminescence flow cytometry. II: Experimental 
evaluation using UV LED excitation,” Cytometry A 71(10), 797–808 (2007). 
21. R. Connally, D. Jin, and J. Piper, “High Intensity Solid-State UV Source for Time-Gated Luminescence 
Microscopy,” Cytometry A 69(9), 1020–1027 (2006). 
22. N. Gahlaut and L. W. Miller, “Time-Resolved Microscopy for Imaging Lanthanide Luminescence in Living 
Cells,” Cytometry A 77(12), 1113–1125 (2010). 
23. O. Rodenko, H. Fodgaard, P. Tidemand-Lichtenberg, P. M. Petersen, and C. Pedersen, “340 nm pulsed UV LED 
system for europium-based time-resolved fluorescence detection of immunoassays,” Opt. Express 24(19), 
22135–22143 (2016). 
24. P. Hedberg and G. Wennecke, “A preliminary evaluation of the AQT90 FLEX TnI immunoassay,” Clin. Chem. 
Lab. Med. 47(3), 376–378 (2009). 
25. T. Lövgren, L. Meriö, K. Mitrunen, M. L. Mäkinen, M. Mäkelä, K. Blomberg, T. Palenius, and K. Pettersson, 
“One-step all-in-one dry reagent immunoassays with fluorescent europium chelate label and time-resolved 
fluorometry,” Clin. Chem. 42(8 Pt 1), 1196–1201 (1996). 
26. S. Eriksson, T. Ilva, C. Becker, J. Lund, P. Porela, K. Pulkki, L.-M. Voipio-Pulkki, and K. Pettersson, 
“Comparison of Cardiac Troponin I Immunoassays Variably Affected by Circulating Autoantibodies,” Clin. 
Chem. 51(5), 848–855 (2005). 
27. CLSI, “Evaluation of Detection Capability for Clinical Laboratory Measurement Procedures; Approved 
Guideline−Second Edition,” CLSI document EP17–A2, Wayne, PA: Clinical and Laboratory Standards Institute 
(2012). 
28. CLSI/NCCLS, “Protocols for Determination of Limits of Detection and Limits of Quantitation; Approved 
Guideline,” NCCLS document EP17-A, Wayne, PA: Clinical and Laboratory Standards Institute (2004). 
29. O. Rodenko, H. Fodgaard, P. Tidemand-Lichtenberg, and C. Pedersen, “340nm UV LED excitation in time-
resolved fluorescence system for europium-based immunoassays detection,” Proc. SPIE 10072, 100720M 
(2017). 
                                                                              Vol. 8, No. 8 | 1 Aug 2017 | BIOMEDICAL OPTICS EXPRESS 3750 
1. Introduction 
Cardiac troponin (cTn) is the preferred biomarker for aid in the diagnosis of acute myocardial 
infarction (AMI) [1]. The recommended decision limit for the myocardial injury is the 99th 
percentile of the healthy reference population. However, recent studies suggest that the 
troponin values in healthy individuals are sex and age dependent [2–5]. Determining the 
biological variation has not been possible with contemporary cTn assays because the assays 
cannot reliably measure and quantify the cTn concentrations of a healthy population, most of 
the assays only detect measurable values in <15% of healthy individuals [6]. Measurement of 
troponin variations in healthy populations will allow for adjustment of the 99th percentile 
values, assist to determine accurate decision limits and thus help in the clinical interpretation 
of the results leading to earlier and improved diagnosis and rule-out of AMI [6–9]. 
For these reasons there has been a need for development of a high-sensitivity troponin 
(hsTn) assay [7,10]. There are two criteria for hsTn (can be troponin I or T) assays: first, the 
coefficient of variation (CV) at the 99th percentile value has to be smaller than or equal to 
10%. Secondly, troponin values of at least 50% (ideally >95%) of the healthy population have 
to be measurable, i.e. above the limit of detection (LoD) [6]. Contemporary cTn assays do not 
satisfy these criteria [6]. Recently, Abbott [5,6,8,10], Siemens Healthcare Diagnostics [2] and 
Roche [4,6,9] have been developing assays which potentially meet these hsTn assay criteria. 
However, these assays are only intended for laboratory use. 
Point-of-care (PoC) immunoassay instruments, in contrast to central laboratory, are 
employed in testing performed near the patient (e.g., in emergency units and intensive care 
departments), with the focus on a short turnaround time and automated testing [11,12]. PoC 
test instruments have approached the performance of central laboratories in terms of 
sensitivity with equal or marginally inferior performance [13,14]. 
Most fluoroimmunoassay instruments are based on time-resolved fluorescence detection 
utilizing lanthanide chelates which are commonly employed due to their long fluorescence 
lifetime and large Stokes shift [15,16]. The widely employed excitation light sources for 
lanthanide chelates were until recently Xenon flash lamps [17,18]. UV LEDs at 365 nm have 
been implemented for flow cytometry [19,20] and fluorescence microscopy [21,22] however 
these do not match the excitation spectra of lanthanides well. 340 nm LEDs have recently 
been used for immunoassay detection with a performance similar to that of flash lamp based 
systems [23]. In that work, the improvement could be achieved only by increasing the 
excitation energy, and with measurements performed manually on a bench-top setup to 
exclude instrument-inherent noise sources e.g. cup-to-cup variation. 
To our knowledge, this is the first report of UV LED optical excitation based point-of-
care immunoassay analyzer outperforming state-of-the-art flash lamp based instruments and 
preliminarily satisfying the hsTn assay criteria when used with a research hsTnI assay. We 
report and compare the test results on a standard TnI assay to a novel point-of-care research 
hsTnI assay. We compare the results to the Radiometer AQT90 FLEX TnI assay with a 
known LoD of 9.5 ng/L, 99th percentile of 23 ng/L, 22 ng/L, 26 ng/L for combined whole 
blood (WB) and plasma, WB alone, and plasma alone, respectively. The 99th percentile was 
determined with WB samples from 231 individuals and plasma samples from 298 individuals 
in a healthy reference population [24]. Using data from the prototype hsTnI assay on the 
Dimension Vista 1500 System (Siemens Healthcare Diagnostics) [2] which meets the hsTn 
criteria and has a ratio of 60 between its 99th percentile value and its LoD, we estimate a 
required LoD of 0.43 ng/L for plasma in order to fulfill the hsTn criteria. We have obtained a 
LoD of 1.9 ng/L on tris-saline-azide buffer containing bovine serum albumin (BSA-TSA) for 
the standard TnI assay and 0.22 ng/L on plasma with the research hsTnI assay, thus 
improving the LoD by factors of 5 and 3 when compared to the flash lamp, respectively. 
Reaching this value is an important step towards hsTnI development for PoC immunoassay 
analysis. Improving the LoD to a level satisfying the hsTn assay criteria will enable detection 
of cTn in >90% of healthy population leading towards early diagnosis of AMI. 
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In section 2, we describe the optimized optical setup that utilizes decreased illumination 
area compared to [23] in order to match the chemically active area of the assays, and list the 
assays employed. In section 3, we first compare the optimized LED based immunoassay 
instrument with state-of-the-art flash lamp based instruments for the standard TnI assay 
analysis. Secondly, we report on the performance of the LED based instrument on a research 
hsTnI assay and compare to the flash lamp based instrument. We show that combining the 
optimized LED based excitation system and the research hsTnI assay we achieve a 
performance preliminarily meeting the hsTn assay criteria. In section 3, we also provide a 
simple model describing the background and noise contributions based on time decay 
constants, which can be generally applied to PoC fluoroimmunoassay instruments. We 
discuss limiting factors in the PoC immunoassay instruments such as cup-to-cup variation and 
its impact on measurement performance. Moreover, we discuss that increasing the excitation 
energy the performance improvement cannot be achieved in an automated measurement due 
to dominating cup-to-cup variation, inevitably appearing in an automated PoC instrument, in 
contrast to benchtop measurements. Finally, in section 4 we conclude the paper. 
2. Methods and materials 
2.1 Optical setup 
The optical system is a reflection-type fluorimeter which includes two subsystems. In the 
excitation subsystem, a single chip UV LED (manufactured by Seoul Viosys Co., Ltd) is used 
as a light source with output power up to 55 mW at 500 mA. An image of the LED is formed 
at the bottom of a test cup with a magnification of 4. The image is 4x4 mm2 in size and takes 
up 45% of cup bottom area which is 6.7 mm in diameter, as shown in Fig. 1, left. The design 
of the excitation optics was modified to obtain smaller magnification at the cost of less 
collected light compared to [23]. In our previous work, the fluorescence signal was lower by 
30% when excited by the LED compared to the flash lamp due to non-optimal overlap of the 
UV illumination area and chemically active area. Considering the conclusions of our previous 
work the illumination area was decreased by 36% to increase the detected fluorescence signal. 
The size of the active fluorescent area was estimated with a scanning fluorimeter to be 
approximately 4 mm in diameter. With the optimized LED system, the fluorescent signal was 
increased by a factor of 2, compared to the first LED system (measured on BSA-TSA samples 
with TnI concentration of 139 ng/L). The detection optical path remains unchanged. The 
emitted fluorescence is detected by a photomultiplier tube (PMT). The two optical paths are 
separated by a dichroic beam splitter and two sets of filters. The LED emission spectrum has 
an intensity peak at 343 nm and a FWHM (defined at half maximum) of 10 nm, which is 4.8 
times narrower than the filtered flash lamp spectrum, as shown in Fig. 1, right. The LED 
based optical units (OU) are compatible with the flash lamp based immunoassay analyzers 
and can be integrated for automated measurements in a standard PoC environment. The 
excitation energy of the LED based instruments is equal to that of the flash lamp based 
instruments. A single measurement consists of 3x861 excitation pulses at a repetition 
frequency of 250 Hz giving a total measurement time of 10.3 s. 
2.2 Assays 
The single wells are prepared according to the all-in-one dry cup technology [25] with 
europium chelate as a fluorescence marker. The long fluorescence lifetime of europium, in 
the range of hundreds of microseconds up to a millisecond [16], allows for the 
implementation of long excitation LED pulses. The assays used in the experiments are 
described below. 
 Assay 1: standard TnI assay of Radiometer AQT90 FLEX [24,26] used to determine the 
improvement of LoD obtained by the LED excitation source compared to the standard 
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flash lamp based system. The europium chelate used for the tracer antibody in the 
standard TnI has an excitation peak at 325 nm. 
 Assay 2: hsTnI research assay utilizing three biotinylated capture antibodies and one 
europium-labelled tracer antibody. 
 Assay 3: hsTnI research assay used in the optimization study is similar to Assay 2 but with 
two tracer antibodies binding to separate epitopes on the TnI molecule. 
The research hsTnI assays 2 and 3 have been developed with the standard TnI assay 
(Assay 1) as a starting point by modifying the chemical components in order to increase 
analytical sensitivity. The research hsTnI assays are also based on the all-in-one dry cup 
technology. 
The TnI assay excitation spectrum is shown in Fig. 1, right (yellow). Both hsTnI assays 
have their excitation peak at 355 nm, as shown in Fig. 1, right (green). The emission peak of 
all assays is at 615 nm. The hsTnI assays have 73% and 28% better spectral overlap 
(calculated using the emission spectra normalized to have equal area under the spectral curve) 
with the LED and filtered flash lamp emission spectra, respectively, compared to the standard 
TnI. For both standard and high-sensitivity TnI assays the LED excitation proved more 
optimal compared to the filtered flash lamp. 
 
Fig. 1. Left: an LED image is formed in the bottom of a test cup which is 6.7 mm in diameter. 
The 4x4 mm2 LED image takes up 45% of the cup area. Right: normalized emission spectra of 
the LED (blue), filtered flash lamp (red) and normalized excitation spectra of the standard TnI 
(yellow) and the research high-sensitivity TnI assays (green). 
3. Results and discussion 
3.1 Optimized LED excitation based measurement of standard TnI assay 
The performance of the LED based instruments was first tested with the standard TnI assay 
(Assay 1). Five fully automated instruments were used in the experiment. The measurements 
from the instruments with a flash lamp OU (AQT90 FLEX manufactured by Radiometer 
Medical) are used as reference baseline for the measurements. Then the flash lamp OUs were 
replaced with the LED OUs. The samples consist of ternary troponin ITC complex (produced 
by HyTest) and troponin complex (by BBI Solutions) diluted in BSA-TSA. The sample TnI 
concentration was 139 ng/L for instrument 1, and 30 ng/L for instruments 2-5. The 
instruments 1-5 are equivalent. 
The relative change of signal of the blank cups (processed with assay buffer (AB), i.e. 
background) decreased with LED excitation for four out of the five instruments, whereas the 
fluorescence signal of the sample cup increased when excited by the LED, as shown in Table 
1. The data for individual test cups measured on instrument 2 is shown in Fig. 2. Compared to 
our previous work [23], the smaller illumination area provides an increased signal. 
To determine the limit of blank (LoB) and the LoD of the instruments with the LED OU, 
we ran a dilution series with TnI concentrations of 1; 2.5; 5; 15; 30 ng/L in BSA-TSA. The 
blank cups were processed with AB. The sample volume was 35 µL. For the first instrument 
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we had 16 replicates for 1; 2.5; 5 ng/L and 8 replicates for 15 ng/L and 30 ng/L. For the other 
four instruments we had 16 replicates at all concentrations. The LoB and LoD were calculated 
using the parametric approach described in the Clinical and Laboratory Standards Institute 
(CLSI) guidelines [27]. The LoB is calculated with blank cups processed with null 
concentration sample as: 
 1.645
11
4( )
B BLoB
B K
μ σ= + ⋅
−
−
 (1) 
Bμ and Bσ are average value and standard deviation of the measured blank cups, respectively. 
B is the number of blank cups replicates measured (of all blank samples in total), and K is the 
number of blank samples used in the experiment (number of subsets of blank cups). The LoD 
was calculated with the low concentration samples of 1; 2.5; 5 ng/L according to: 
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 (2) 
L is the total number of low concentration sample results, i.e. total number of replicates of all 
concentrations used in the calculation. J is number of the low concentration samples used in 
the experiment, ni is number of results for i-th low concentration sample, and iσ is standard 
deviation of the distribution of replicates of i-th low concentration sample. The limits of 
quantification (LoQ) were calculated by fitting a power fit function to the CV vs. 
concentration curve shown in Fig. 3, right (fits not shown). 
Table 1. Relative change of the averaged fluorescence signal of sample cups with a 
concentration of 30 ng/L and blank cups, after the flash lamp OUs were replaced by the 
optimized LED based OUs measured with the TnI assay 
Instrument 1 2 3 4 5 
Relative change of sample 
cups averaged signal, % + 57
a + 25 + 40 + 18 + 17 
Relative change of blank 
cups averaged signal (null 
concentration), % 
−28 −26 + 17 −28 −47 
adata for 139 ng/L sample 
The LoBs are calculated to be in the range from 0.8 ng/L to 1.1 ng/L, and the LoDs are in 
the range from 1.5 ng/L to 2.1 ng/L for the five LED based instruments as shown in Table 2. 
We compare the calculated values of the LoB and LoD to the data of the standard TnI assay 
measured in the current platform AQT90 FLEX [24], where the reported experiment was 
performed according to the CLSI EP17-A protocol [28]. The reported LoB was 4.3 ng/L, LoD 
9.5 ng/L, and the concentration that corresponded to CV of 10% and 20% was 24 ng/L and 18 
ng/L for WB, and 24 ng/L and 16 ng/L for plasma, respectively. In our experiment the LoB 
was improved by a factor of 4.7 corresponding to the decreased background value. The LoD 
was improved by factor of 5. However, it should be noted that our experiments are 
preliminary in the sense that it does not contain the full required number of replicates as 
recommended by [27]. 
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 Fig. 2. Fluorescence signal of 16 replicates measured on Instrument 2 for the flash lamp based 
analyzer (baseline measurement) and with the optimized LED based unit: for blank cups 
(processed with AQT90 FLEX assay buffer) and BSA-TSA buffer containing 30 ng/L TnI. 
The fluorescence signal at the concentration of 30 ng/L has increased by 25% whereas the 
background (concentration 0 ng/L) dropped by 26%. 
 
Fig. 3. SNR (left) and CV (right) of the five LED based instruments measured on TnI assay. 
Table 2. LoB, LoD and LoQ of the five LED based instruments measured on BSA-TSA 
buffer based TnI samples with TnI assay compared to the current state-of-the art flash 
lamp based instrument 
 BSA-TSA buffer based samplesa Plasma or WB samples 
Instrument 1 2 3 4 5 Radiometer AQT90 FLEX [24] 
LoB, ng/L 0.8 0.9 1.1 0.8 1.0 4.3 
LoD, ng/L 1.5 1.9 2.1 1.9 2.0 9.5 (plasma) 
LoQ (CV 20%), ng/L 1.9 2.5 3.3 2.7 2.4 18 (whole blood) 16 (plasma) 
LoQ (CV 10%), ng/L 5.8 6.9 8.4 7.3 6.8 24 (whole blood) 24 (plasma) 
Averaged background 
value Bμ , counts 204 214 281 195 149 
 
Background standard 
deviation Bσ , counts 
19 18 20 15 14 
 
aLOB determined on AB samples 
We calculate the signal-to-noise ratios (SNR) as
2 2
S B
S B
SNR μ μ
σ σ
−
=
+
, where Sμ  is the signal 
averaged over N sample cups, Bμ  is the background averaged over N blank cups, and Sσ  is 
the standard deviation of the signal. The value Sμ is the number of photons detected and 
S Bμ μ−  is the useful fluorescence signal, or specific signal. The CVs are calculated for the 
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measured concentration. SNR and CV as a function of the sample concentration are shown in 
Fig. 3. 
3.2 Measurement of the research hsTnI assay with the LED based instrument 
In this section we present the results of the LED based instrument using the research hsTnI 
assay (Assay 2). Details of the novel assay will be published elsewhere. We ran nine BSA-
TSA samples, four lithium heparin (LiHep) plasma samples, five ethylenediaminetetraacetic 
acid (EDTA) plasma samples and two serum samples. The concentration values and number 
of replicates for each level are shown in Table 3. The sample volume was 80 µL (increased 
compared to 35 µL used previously), the shaking speed was increased by factor of 2.5 to 
improve the chemical reaction efficiency. Additionally, a parabolic shaped specular reflector 
was placed under the test cup instead of a flat diffuse reflector. These changes were proven to 
make a positive impact on the detected signal (unpublished data). The LoB is calculated 
according to Eq. (1) based on measurements of both BSA-TSA and AB processed blank cups. 
The LoD is calculated according to Eq. (2) based on a combination of 1) low sample signals 
from the three low level BSA-TSA samples, 2) estimated standard deviation from all BSA-
TSA samples, 3) the specific signal level (signal/concentration) of the plasma and serum 
samples. 
The LoD measured with the LED based instrument on plasma with the hsTnI assay was 
0.22 ng/L. The hsTnI assay showed a LoD of 0.67 ng/L measured with the flash lamp based 
instrument and no hardware changes compared to the AQT90 FLEX instrument. The CV as a 
function of sample concentration for the BSA-TSA and plasma samples is shown in Fig. 4, 
measured on the hsTnI assay using both the AQT90 FLEX instrument and the optimized LED 
based instrument. The CV was improved significantly using the LED based OU. The obtained 
LoD of the LED based instrument is improved by factor of 3 compared to the LoD of the 
AQT90 FLEX, see Table 4. 
Table 3. Samples used in the hsTnI assay measurements 
Sample BSA-TSA 
Concentration, ng/L 0.29 0.59 0.83 1.4 2.2 4.1 8.9 17 46 
Number of replicates 10 10 10 10 5 5 5 5 5 
Sample Lithium heparin (LiHep) plasma     
Concentration, ng/L 0.64 1 1.8 9.3      
Number of replicates 5 5 5 5      
Sample EDTA plasma       
Concentration, ng/L 0.8 1.1 0.62 8.4 0.23     
Number of replicates 5 5 5 5 5     
Sample Serum        
Concentration, ng/L 0.77 12.4        
Number of replicates 5 5        
Table 4. LoB and LoD measured with the LED based instrument and the flash lamp 
based instrument (AQT90 FLEX) on the hsTnI assay 
Instrument LED based AQT90 FLEX (flash lamp based) 
LoB, ng/L 0.12 0.35 
LoD on plasma, ng/L 0.22 0.67 
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 Fig. 4. CV vs. concentration measured on BSA-TSA samples (left) and plasma samples (right) 
with the LED based analyzer and the AQT90 FLEX analyzer (flash lamp based instrument) 
with the research hsTnI assay. 
In order to estimate the required LoD to fulfill the hsTn assay criteria, we use the data of a 
prototype hsTnI assay measured with the Dimension Vista 1500 System (Siemens Healthcare 
Diagnostics), with reported LoD of 0.8 ng/L and the 99th percentile value of 48 ng/L [2]. The 
ratio between the 99th percentile and the LoD is 60, and measurable values of hsTnI were 
detected in 88% of the healthy reference cohort. Using the 99th percentile value determined 
for the standard TnI assay of 26 ng/L for plasma, based on 298 plasma samples (152 female 
and 146 male) [24], we estimate the required LoD to be 0.43 ng/L. The obtained LoD is about 
a factor of two lower than this value. Based on the set arguments above we expect that the 
obtained improvement will allow us to meet the hsTnI criteria for PoC applications. The final 
proof will involve the determination of the 99th upper reference limit with the LED based 
instrument and include a large study of the healthy reference population which will be 
performed later. 
3.3 Optimization of the time-resolved fluorescence detection 
The background and noise sources in the immunoassay detection system determine the 
measurement performance, i.e. LoB and LoD. Therefore, it is crucial to understand the main 
contributors. We discuss the background and noise sources in the following model. The 
background contributions in the system are the following: 
 total OU cup chem darkB B B B B= + + +  (3) 
OUB  is the background fluorescence from the optical unit (no temporal dependence), cupB  is 
the fluorescence of the empty cup (with a decay time of hundreds of µs), chemB  is the 
contribution originated from non-specific binding of tracer antibodies with fluorescent 
markers to the inner walls of the cup (with a decay time of the europium chelate of ms) and 
darkB  is a constant contribution from the detector (dark counts of the PMT). The first three 
sources of the background depend on the excitation light intensity, whereas the detector 
contribution is independent of the excitation light but is a function of temperature. The 
absolute values of all contributions for both the LED OU and flash lamp OU were reported in 
[29]. Correspondingly, the noise of the measurement is defined as: 
 . .s shot b shot c l iN N N N N N= + + + +  (4) 
N represents variance, or squared standard deviation, and .s shotN  is the shot noise of the useful 
fluorescence signal, .b shotN  is the shot noise of the total background defined in Eq. (3), and 
cN , lN , iN  are cup-to-cup, lot-to-lot and instrument-to-instrument variations, respectively. 
These three noise contributions are not directly related to the background contributions. The 
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cup-to-cup variation can originate both from the variation of individual empty cups ( cupB ), 
from the difference in the chemical compositions of the cups ( chemB ) and from the variation of 
cups processing in the instrument (e.g. washing). The lot-to-lot variation is caused by both 
cupB  and chemB . The instrument-to-instrument variation includes the variation of the 
background of the instrument ( OUB ) and the variation of optical component parameters in the 
OU. 
Table 5. Fluorescence decay lifetime constants of an empty cup and BSA-TSA samples 
with a TnI concentration of 0 ng/L (blank cup), 0.25 ng/L and 30 ng/L obtained by curve 
fitting for replicates measured on one instrument 
 Empty cup Blank cup (BSA-TSA + 0 ng/L TnI) 
BSA-TSA + 0.25 
ng/L TnI 
BSA-TSA + 30 
ng/L TnI 
Decay constant(s), µs 
Average (standard deviation) 155.6 (84.1) 
124.0 (43.6) 
1049.6 (168.1) 
128.6 (42.8) 
1108.0 (142.7) 1168.1 (8.8) 
Replicates 16 32 32 8 
Table 6. Statistical data measured on four instruments with the hsTnI assay 
Instrument 
Blank cups BSA-TSA + 0 ng/L TnI BSA-TSA + 0.25 ng/L TnI 
Averaged 
signal, counts 
Standard 
deviation, 
counts 
CV, % 
Averaged 
signal, 
counts 
Standard 
deviation, 
counts 
CV, % 
6 1128 56 4.9 1510 56 3.7 
7 1441 82 5.7 1866 67 3.6 
8 1410 57 4.0 1862 67 3.5 
9 1306 82 6.2 1850 125 6.7 
All instruments 1320 142 10.7 1773 172 9.7 
 
Fig. 5. Fluorescence decays of empty cup (red), blank cup (green), and cup processed with the 
sample of 0.25 ng/L with the hsTnI assay (blue). 
In this optimization study we used the research hsTnI assay (Assay 3) to experimentally 
determine optimum timing parameters of the time-resolved detection of lanthanide-based 
chelates. Four LED based instruments were employed in the experiments, where the LED 
OUs were supplemented with a parabolic shaped specular reflector. No other hardware 
changes were made (normal sample volume, normal shaking speed). We ran dilution series of 
ternary troponin complex diluted in BSA-TSA buffer with concentrations of 0; 0.25; 0.5; 1; 5; 
30 ng/L. Here the blank samples were processed with BSA-TSA null concentration buffer. 
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We have analyzed the decay time constants of empty cups (polystyrene only), blank cups 
(processed with BSA-TSA with null concentration), low concentration sample of 0.25 ng/L 
and high concentration sample of 30 ng/L. Data is averaged for 16 replicates for the empty 
cup, 32 replicates of the blank cup and the 0.25 ng/L sample, and for 8 replicates using 30 
ng/L. The 16 replicates of empty cup showed variation CV of 10.7% of detected counts. We 
fitted a single exponential function to all replicates and obtained an average lifetime 
fluorescence decay of 155.6 µs with a standard deviation of 84.1 µs (CV 54.0%) with added 
constant background from the optical unit as shown in Fig. 5 (red curve) and Table 5. The 
constant term is calculated to be 23.4 ± 4.0 counts. The blank cup which includes chemical 
immunocomplexes before the processing, exhibits double exponential fluorescence decay 
with the time constants of 124.0 ± 43.6 µs and 1049.6 ± 168.1 µs. We believe that the short 
fluorescence decay of 124.0 comes from the empty cup and that the long decay is caused by 
non-specific binding of tracer antibodies (with europium chelate attached) to the inner walls 
of the cup. However, due to high variation of empty and blank cups the fitting data should be 
interpreted with caution. The decay curve of the cup processed with a low concentration 
sample of 0.25 ng/L shows the same double exponential behavior. The cup processed with the 
high concentration sample of 30 ng/L shows only a single long lifetime exponential decay of 
1168.1 ± 8.8 µs because the europium fluorescence decay dominates the signal. 
Table 6 presents statistical data for the blank cups and the sample cups with a 
concentration of 0.25 ng/L for four LED based instruments measured on the hsTnI assay. The 
cup-to-cup variation of blank cups, measured on one instrument, does not exceed 10% for all 
four instruments. However, instrument-to-instrument variation is 10.7%. For the sample cups 
with a concentration of 0.25 ng/L, the variation between the instruments is also larger than the 
cup-to-cup variations. In the following, we average the data for the cup replicates but present 
the instruments separately, thus only cup-to-cup variations are present. 
 
Fig. 6. SNR calculated for four LED based instruments measured on BSA-TSA samples with a 
TnI concentration of 0.25 ng/L as a function of the timing parameters: t1 as pre-delay time (i.e. 
time after the end of the excitation pulse before the measurement), and t2 as duration of the 
measurement time window. 
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 Fig. 7. SNR calculated for four LED based instruments with currently employed settings with 
the pre-delay time of 400 µs and the measurement window duration of 400 µs, measured on 
BSA-TSA samples with the novel hsTnI assay. Black star points represent average value for 
the LED based instruments measured on the standard TnI assay. 
 
Fig. 8. LoD calculated for four LED based instruments as a function of the pre-delay time t1 
and duration of the measurement time window t2. 
The optimal timing parameters such as pre-delay time, i.e. the time between the end of the 
excitation pulse and the measurement window, and the duration of measurement time are 
determined by the fluorescence decay constants of the europium chelate and the background 
noise in the system. In the following, we analyze the impact of these timing parameters on the 
SNR as shown in Fig. 6 for a concentration of 0.25 ng/L, where t1 is the pre-delay time and t2 
refers to the duration of the measurement. The optimum pre-delay time has to be longer than 
the decay time of the short fluorescent cup background signal (see Table 5), i.e. 300-400 µs 
after the excitation pulse. The longer measurement window improves the SNR due to higher 
signal. At high concentrations such as 30 ng/L the impact of the timing parameters is not 
evident due to the high europium signal, however, at low concentrations SNR is improved as 
suggested. The data contains the cup variation as described above. The noise of the 
measurement and the SNR are dominated by the cup-to-cup variation as explained in the 
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following. With one set of cups as presented here, division of the replicates into two equal 
sized groups, a calculation of the SNR for the two groups lead to slightly different results, 
where the behavior of the SNR is not necessarily maintained. This confirms the conclusion 
that the cup-to-cup variation is larger than the effect of timing parameters on the SNR. 
Correspondingly, when increasing the excitation energy the improvement is not obtained 
because the cup-to-cup noise contribution dominates over the shot noise. 
The SNR calculated for the LED based instruments configured with standard timing 
parameters (pre-delay of 400 µs and measurement window of 400 µs) is shown in Fig. 7. The 
SNR is improved for the hsTnI assay compared to the TnI assay when measured with the 
LED based instruments, compared to Fig. 3. The SNR generally improves at lower 
concentrations. However at a concentration of 30 ng/L the improvement is not seen 
supposedly due to high cup-to-cup variations. 
The LoD was calculated according to Eq. (2) from the samples with low concentrations of 
0.25; 0.5; 1 ng/L as shown in Fig. 8. The LoD is in the range of 0.8-1.2 ng/L and is optimum 
for the longer pre-delay time and longer measurement time as discussed above. However, it 
did not exhibit a strong dependence on the parameters, excluding the case with the shortest 
both pre-delay time and measurement window. The LoD is higher than that obtained in 
section 3.2, probably because the experiment was performed on BSA-TSA samples, with 
slightly different hsTnI assay (two tracer antibodies vs. one tracer antibody) and without the 
two mentioned platform changes: larger sampling volume and accelerated shaking. 
4. Conclusion 
In this paper, we have tested a novel LED excitation based immunoassay instrument intended 
for PoC use. The laboratory tests were performed with a standard TnI assay and a research 
prototype hsTnI assay. The LoD was improved by a factor of 5, from 9.5 ng/L to 1.9 ng/L, for 
the standard TnI assay when measured with the LED based instrument, significantly 
outperforming the state-of-the-art flash lamp OU based instrument. The improvement was 
achieved primarily by optimizing the overlap between the UV illumination area and the 
chemically active area where the immunocomplexes are located. 
In the implementation of the novel research hsTnI assay with the LED based instrument 
we have obtained a detection limit of 0.22 ng/L measured on plasma, showing an 
improvement by a factor of 3 compared to the flash lamp based instrument. Using data for an 
existing hsTnI assay from an external manufacturer, we estimated the required value of LoD 
to be 0.43 ng/L in order to meet the hsTnI criteria. The combination of the LED excitation 
and the prototype hsTnI assay enabled the LoD of 0.22 ng/L, which is 49% below the 
estimated requirement. We believe our preliminary results are an important step in the 
development of the hsTnI assay in PoC testing and that the hsTnI criteria will soon be 
documented in PoC systems using LED excitation, ultimately leading to more accurate 
interpretation of clinical tests and earlier diagnosis and rule-out of AMI. 
We suggest a model which includes the background and noise contributions to describe 
immunoassay detection. The model can be generally applied to lanthanide-based 
heterogeneous time-resolved fluoroimmunoassays. We showed that the temporal decay of the 
background in the system includes two exponential terms. The SNR can be improved by 
choosing the optimal pre-delay time to largely match the short background decay time (about 
hundreds of µs), whereas the long lifetime decay term originating from the non-specific 
binding of the tracer antibodies to the cups inner walls cannot be filtered. We also 
demonstrate that the cup-to-cup variation is a dominating noise contributor that is limiting the 
instrument performance. 
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